IMV (IMVIF) ROCE %: -155.92% (As of Dec. 2022)

What is IMV ROCE %?

IMV IMVIF -99.95% 12 ROCE % is -155.92% as of Dec. 2022. GuruFocus rates IMVIF with a GF Score™ of 12/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IMV's annualized ROCE % for the quarter that ended in Dec. 2022 was -155.92%.

IMV (OTCPK:IMVIF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IMV ROCE % Related Terms

IMV ROCE % Historical Data

* Premium members only.

The historical data trend for IMV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMV ROCE % Chart

IMV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-134.76

-170.79

-103.88

-90.72

-122.61

IMV Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial															-110.54	-113.29	-126.54	-143.59	-155.92

12GF Score

IMV Inc IMVIF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IMV ROCE % Calculation

IMV's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-38.492	/	( ( (50.121 - 9.263)	+	(31.348 - 9.42) )	/ 2 )
	=	-38.492	/	( (40.858	+	21.928)	/ 2 )
	=	-38.492	/	31.393
	=	-122.61 %

IMV's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-34.36	/	( ( (32.272 - 10.126)	+	(31.348 - 9.42) )	/ 2 )
	=	-34.36	/	( ( 22.146	+	21.928 )	/ 2 )
	=	-34.36	/	22.037
	=	-155.92 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -155.92% mean?

IMV (IMVIF) has a ROCE % of -155.92% as of Dec. 2022.

Is IMV's ROCE % too high?

IMV's current ROCE % is -155.92%. Overall, IMV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does IMV's ROCE % compare to RGTPQ and QBIO?

IMV's ROCE % of -155.92% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. IMV's current ROCE % is -155.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IMV stock overvalued right now?

IMV (IMVIF) has a current ROCE % of -155.92%. The current ROCE % is -155.92%. IMV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For IMV (IMVIF), the current ROCE % is -155.92% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMV Business Description

Industry Healthcare Biotechnology

Comparable Companies RGTPQ QBIO RGIN ATRX IVRN GLSHQ HGEN USRM RGMP NOVNQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Address 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, NS, CAN, B3B 2C4

Website https://www.imv-inc.com

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system.

12GF Score

Get the complete analysis for IMVIF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View IMVIF Analysis

See ROCE % data for all stocks →